Zurich consensus: Statement of German experts on stgallen conference 2011 on breast cancer (Zurich 2011);St.-Gallen-Konferenz 2011 zum primären Mammakarzinom: Meinungsbild deutscher Experten (Zürich 2011)

Geburtshilfe und Frauenheilkunde

Volumn 71, Issue 5, 2011, Pages 381-390

  Untch, M ^a   Gerber, B ^b   Mobus V ^c   Schneeweiss, A ^d   Thomssen, C ^e   Von Minckwitz, G ^f   Beckmann, M W ^g   Blohmer, J U ^h   Costa, S D ⁱ   Diedrich, K ^j   Diel, I ^k   Eiermann, W ^l   Friese, K ^m   Harbeck, N ⁿ   Hilfrich, J ^o   Jackisch, C ^p   Janni, W ^q   Janicke F ^r   Jonat, W ^s   Kaufmann, M ^c   Kiechle, M ^t   Kohler U ^u   Kreienberg, R ^v   Maass, N ^w   Marschner, N ^x   Nitz, U ^y   Scharl, A ^z   Wallwiener, D ^aa   more..

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b Universitatsfrauenklinik Rostock   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^f GERMAN BREAST GROUP   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h MARTIN LUTHER KRANKENHAUS   (Germany)

ⁱ UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k Gemeinschaftspraxis Gynäkologie und Geburtshilfe   (Germany)

^l Frauenklinik   (Germany)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^o Eilenriedeklinik   (Germany)

^p Klinikum Offenbach   (Germany)

^q UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^r UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^s UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^t TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^u Klinikum St Georg   (Germany)

^v UNIVERSITY HOSPITAL ULM   (Germany)

^w UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^x Gemeinschaftspraxis für Interdisziplinäre Onkologie und Hämatologie   (Germany)

^y Bethesda Monchengladbach GmbH   (Germany)

^z KLINIKUM ST MARIEN   (Germany)

^aa UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

more..

Author keywords

early breast cancer; endocrine therapy; neoadjuvant chemotherapy; predictive prognostic marker; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; GERMANY; HUMAN; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; TREATMENT INDICATION;

EID: 79957653428     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0030-1271133     Document Type: Conference Paper

References (9)

1. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. JCO 2006 24 3726-3734 (Pubitemid 46622311)
2. Albain K, Barlow W E., Ravdin P M. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol 2010 11 55-65
3. Lyman G L., Giuliano A E., Somerfield M R. et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005 23 7703-7720 (Pubitemid 46291835)
4. Whelan T, Pignol J P., Levine M N. et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010 362 513-520
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 365 1687-1717
6. Nitz U et al. Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase lll trial EC-Doc. SABCS2008; Abstract No. 551601
7. Moebus V, Jackisch C, Lueck H J. et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010 28 2874-2880
8. Slamon D et al. Use of trastuzumab in the adjuvant treatment of HER2-positive breast cancer: efficacy and safety results from the BCIRG-006 study. NEJM 2011 in press
9. Naume B, Sorlie T. Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome. Breast Cancer Research 2005 7 (Suppl.2) 35